title: Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion.
abstract: OBJECTIVE
  When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center.
  
  
  METHODS
  Retrospective review of all patients with symptomatic VMA treated with ocriplasmin from January 2013 through May 2013 at a single center.
  
  
  RESULTS
  Nineteen patients with symptomatic VMA received intravitreal ocriplasmin. Eight patients (42%) exhibited resolution of VMA. Macular holes in three of six patients (50%) closed after injection. A higher proportion of VMA resolution was observed in patients with the following baseline characteristics: age less than 65 years, focal adhesions less than or equal to 1,500 μm, presence of macular hole, phakic status, and absence of epiretinal membrane.
  
  
  CONCLUSIONS
  Initial clinical outcomes using ocriplasmin in this study are consistent with those reported in the phase 3 clinical trials. Improved clinical results can be achieved with careful case selection based on specific baseline characteristics.
authors.affiliation: Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Kim
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Schwartz
authors.forename: William E
authors.initials: WE
authors.lastname: Smiddy
authors.forename: Rishi R
authors.initials: RR
authors.lastname: Doshi
authors.forename: Jaclyn L
authors.initials: JL
authors.lastname: Kovach
authors.forename: Audina M
authors.initials: AM
authors.lastname: Berrocal
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Moshfeghi
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Fortun
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D012164:Retinal Diseases / Q000188:drug therapy*; D012167:Retinal Perforations / Q000188:drug therapy; D012189:Retrospective Studies
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin